

composition;

- (c) a hydrophilic polymer comprising a controlled particle size in the drug composition;
- (d) a means for delaying release of drug from the drug composition.


The dosage form of Claim wherein the drug is verapamil hydrochloride.

The dosage form of Claim wherein the drug possesses a controlled particle size of up to 150 μm and the hydrophilic polymer possesses a controlled particle size of up to 250 μm.

A method for the manufacture of a dosage form adapted to release a drug at a rate having a percentage deviation of not more than 5% from a mean release rate over a prolonged period of time comprising:

- (a) controlling a drug particle size;
- (b) controlling a hydrophilic polymer particle size;
- (c) admixing the drug with the hydrophilic polymer;
- (d) providing a means for prolonging release of the drug.

A8. A method for the manufacture of a dosage form according to claim wherein the drug is verapamil hydrochloride.



A method for the manufacture of a dosage form according to claim wherein the prolonged release is four hours or more.


A method for the manufacture of a dosage form according to claim 47 wherein the drug particle size is controlled to up to 150 μ m, and the hydrophilic polymer particle size is controlled to up to 250 μ m.

A method for maintaining a percentage deviation in a drug release rate of not more than 5% from the mean release rate over a prolonged period of time comprising:

- (a) controlling a drug particle size;
- (b) controlling a hydrophilic polymer particle size;
- (c) admixing the drug with the hydrophilic polymer;
- (d) providing a means for prolonging release of the drug.

Markov A method for providing a controlled drug rate of release from a dosage form in a patient, wherein the method comprises:

(a) admitting orally into the patient a therapeutic composition comprising a dose of drug with the drug possessing a controlled particle size, and a hydrophilic polymer for the drug possessing a controlled particle size; and



(b) codelivering the drug and the accompanying hydrophilic polymer at a substantially constant rate of release from the composition to provide an effective therapeutic dose in the patient.

The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 52, wherein the substantially constant rate of release from the composition has a percentage deviation of not more than 5% from the mean release rate over a prolonged period of time.

The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 53, wherein the prolonged period of time is four hours or more.

The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 52, wherein the controlled particle size of the drug is up to 150 μ m, and the controlled particle size of the hydrophilic polymer is up to 250 μ m.

A method for providing a rate of release from a dosage form in a patient having a percentage deviation of not more than 5% from the mean release rate over a prolonged period of time, wherein the method comprises:

(a) admitting orally into the patient a therapeutic composition comprising a



- (a) admitting orally into the patient a therapeutic composition comprising a dose of drug with the drug possessing a controlled particle size, and a hydrophilic polymer possessing a controlled particle size; and
- (b) codelivering the drug and the accompanying hydrophilic polymer at a substantially constant rate of release from the composition to provide an effective therapeutic dose in the patient.

The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 56, wherein the prolonged period of time is four hours or more.

The method for providing a controlled drug rate of release from a dosage form in a patient according to claim 5° , wherein the drug possesses a controlled particle size of up to 150 μ m, and the hydrophilic polymer possesses a controlled particle size of up to 250 μ m.

<u>REMARKS</u>

Claims 1-43 are cancelled without prejudice.

Claims 44-58 were added.

Attached hereto is a clean copy of the changes made to the claims by the current amendment. The attached page is captioned "Clean Copy of Claims."